SEC 13F Intelligence

Managers / Q4 2020 · view latest →

Endurant Capital Management LP

CIK 0001633055 · 66 BOVET ROAD, SUITE 353, SAN MATEO, CA, 94402 · 650-539-5905

Reported Value
$277M
Q4 2020
Positions
52
Filings on Record
24
2019–present window
Filed
Feb 16, 2021
original filing

Summary

Endurant Capital Management LP reported $277M in U.S.-listed holdings across 52 positions for Q4 2020.

Its largest position, Oxford Immunotec Global, represents 14.1% of the portfolio.

Compared with Q3 2020, the fund opened 21 new positions and exited 29.

Portfolio Metrics

Turnover
+39.6%
vs prior filed quarter
Top-10 Concentration
+46.9%
share of reported value
Largest Position
+14.1%
Oxford Immunotec Global
New / Exited
21 / 29
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $189MQ4 ’18Q1 ’19: $253MQ2 ’19: $254MQ3 ’19: $279MQ3 ’19Q4 ’19: $317MQ1 ’20: $221MQ2 ’20: $1.8BQ2 ’20Q3 ’20: $338MQ4 ’20: $277MQ1 ’21: $384MQ1 ’21Q2 ’21: $364MQ3 ’21: $439MQ4 ’21: $414MQ4 ’21Q1 ’22: $380MQ2 ’22: $285MQ3 ’22: $307MQ3 ’22Q4 ’22: $246MQ1 ’23: $195MQ2 ’23: $115MQ2 ’23Q3 ’23: $111MQ4 ’23: $17MQ1 ’24: $0Q1 ’24filingsflow.com

Portfolio Composition

By security type
Common Stock: 70.9%Other: 23.0%ADR: 5.8%US DOMESTIC: 0.2%
  • Common Stock · 70.9% · $197M
  • Other · 23.0% · $64M
  • ADR · 5.8% · $16M
  • US DOMESTIC · 0.2% · $638,000

Quarter-over-Quarter Changes full breakdown →

vs Q3 2020 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
BDXBECTON DICKINSON & CONEW+69.3K69.3K+$17M$17M
ABGAMERISOURCEBERGEN CORPNEW+78.3K78.3K+$8M$8M
SNNSMITH & NEPHEW PLCNEW+179.1K179.1K+$8M$8M
ELUTAZIYO BIOLOGICS INCNEW+408.2K408.2K+$6M$6M
ACHOWENS & MINOR INC NEWNEW+204.4K204.4K+$6M$6M
AVTRAVANTOR INCNEW+194.8K194.8K+$5M$5M
SRPTSAREPTA THERAPEUTICS INCNEW+28.4K28.4K+$5M$5M
LABORATORY CORP AMER HLDGSNEW+19.8K19.8K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2020

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1OXFORD IMMUNOTEC GLOBAL PLCORD SHS14.11%$39M2.24M
2BDXBECTON DICKINSON & COhistory →COM6.25%$17M69.3K
3BMYBRISTOL-MYERS SQUIBB COhistory →COM5.46%$15M244.1K
4TREURTRILLIUM THERAPEUTICS INChistory →COM NEW3.48%$10M655.7K
5ABBVABBVIE INChistory →COM3.27%$9M84.5K
6JNJJOHNSON & JOHNSONhistory →COM3.19%$9M56.2K
7KIDSORTHOPEDIATRICS CORPhistory →COM2.87%$8M193.0K
8ABGAMERISOURCEBERGEN CORPhistory →COM2.76%$8M78.3K
9SIBNSI BONE INChistory →COM2.75%$8M254.9K
10SNNSMITH & NEPHEW PLChistory →SPDN ADR NEW2.72%$8M179.1K
11ACRSACLARIS THERAPEUTICS INChistory →COM2.63%$7M1.13M
12ELVANTHEM INChistory →COM2.62%$7M22.6K
138INSYNEOS HEALTH INChistory →CL A2.50%$7M102.0K
14MOLECULAR TEMPLATES INCCOM2.31%$6M681.2K
15FATEFATE THERAPEUTICS INChistory →COM2.18%$6M66.6K
16EHCENCOMPASS HEALTH CORPhistory →COM2.18%$6M73.1K
17OCULOCULAR THERAPEUTIX INChistory →COM2.17%$6M290.5K
18ADAPYADAPTIMMUNE THERAPEUTICS PLChistory →SPONDS ADR2.10%$6M1.08M
19AHCOADAPTHEALTH CORPhistory →COM CL A2.04%$6M150.4K
20ELUTAZIYO BIOLOGICS INChistory →COM CL A2.01%$6M408.2K
21ACHOWENS & MINOR INC NEWhistory →COM1.99%$6M204.4K
22AVTRAVANTOR INChistory →COM1.98%$5M194.8K
23ESPRESPERION THERAPEUTICS INC NEhistory →COM1.94%$5M207.3K
24CICIGNA CORP NEWhistory →COM1.88%$5M25.1K
25SRPTSAREPTA THERAPEUTICS INChistory →COM1.74%$5M28.4K
26IM8NINSMED INChistory →COM PAR $.011.49%$4M124.3K
27LABORATORY CORP AMER HLDGSCOM NEW1.46%$4M19.8K
28SUTRO BIOPHARMA INCCOM1.35%$4M172.0K
29MBIOUSDMUSTANG BIO INChistory →COM1.22%$3M892.0K
30GDRXGOODRX HLDGS INChistory →COM CL A1.13%$3M77.4K
31HUMHUMANA INChistory →COM1.11%$3M7.5K
32SELECTA BIOSCIENCES INCCOM1.08%$3M990.6K
33AZNNASTRAZENECA PLChistory →SPONSORED ADR1.03%$3M56.9K
34ANGOANGIODYNAMICS INChistory →COM1.02%$3M184.9K
35PRAHPRA HEALTH SCIENCES INCCOM0.98%$3M21.6K
36IOVAIOVANCE BIOTHERAPEUTICS INCCOM0.91%$3M54.2K
37KINIKSA PHARMACEUTICALS LTDCOM CL A0.85%$2M133.6K
38CNCCENTENE CORP DELCOM0.83%$2M38.3K
39VTLUSDIMMUNIC INCCOM0.76%$2M138.6K
40ZTSZOETIS INCCL A0.76%$2M12.7K
41APTOSE BIOSCIENCES INCCOM NEW0.75%$2M477.9K
42EUCRATES BIOMEDICAL ACQU CORUNIT 10/23/20270.75%$2M195.0K
43PROTHENA CORP PLCSHS0.66%$2M151.8K
44BDQMALBIREO PHARMA INCCOM0.57%$2M42.3K
45MRKMERCK & CO. INCCOM0.44%$1M14.9K
46QUOTIENT LTDSHS0.43%$1M226.6K
47PNTGPENNANT GROUP INCCOM0.38%$1M18.2K
48MEDAVAIL HOLDINGS INCCOM0.34%$955,00063.5K
49SENSEONICS HLDGS INCNOTE 5.250% 2/00.23%$638,0001.50M
50AKARI THERAPEUTICS PLCSPONSORED ADR0.14%$382,000206.6K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2024$01May 7, 202413F-HRchanges · EDGAR ↗
Q4 2023$17M25Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$111M43Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$115M34Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$195M50May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$246M55Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$307M49Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$285M50Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$380M63May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$414M68Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$439M53Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$364M57Aug 27, 2021RESTATEMENTchanges · EDGAR ↗
Q1 2021$384M61May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$277M52Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2020$338M60Nov 16, 202013F-HRchanges · EDGAR ↗
Q2 2020$1.8B56Aug 14, 202013F-HRchanges · EDGAR ↗
Q1 2020$221M51May 15, 202013F-HRchanges · EDGAR ↗
Q4 2019$317M54Feb 14, 202013F-HRchanges · EDGAR ↗
Q3 2019$279M49Nov 25, 2019RESTATEMENTchanges · EDGAR ↗
Q2 2019$254M50Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$253M70May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$189M48Feb 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.